Nanobody-based column separation technology for molecular assay sample preparation

Technology
Conceptual
Company

Innovative column separation technology using a synthetic nanobody library for selective sample preparation in molecular assays. It offers precise filtering of desired species and removal of contaminants.

Overview

Quantitative BioSciences, Inc. introduces a groundbreaking column separation technology utilizing a vast synthetic nanobody library for molecular assay sample preparation. Nanobodies, smaller and highly sensitive versions of antibodies, provide selective filtering to retain desired species and eliminate contaminants. This technology is adaptable for various molecular assays, offering precise and efficient sample preparation.

Technical specifications
  • Nanobody library: A synthetic library comprising 10^11 members, enabling high diversity and specificity.
  • Sample preparation: Targets specific species for retention while removing unwanted contaminants.
  • Adaptability: Can be tailored to meet specific customer needs by selecting appropriate nanobodies and conditions.
  • Application areas: Ideal for use in diverse molecular assays where contamination-free samples are critical.
Technology readiness level

This technology is currently at TRL 3, with experimental proof of concept achieved. Future validation will involve collaboration with customers to refine column properties and optimize performance for specific applications.


About Quantitative BioSciences, Inc.

Quantitative BioSciences, Inc. (QBI) is a biotechnology company that integrates bioengineering, synthetic biology, and bioinformatics to develop custom biosensing and immunoassay solutions. Founded in 2010, the company built the Qube platform, an at-line, autonomous sensing system designed for continuous, multiplexed, and quantitative monitoring of various analytes, including proteins, pathogens, chemicals, and environmental contaminants. Their technology utilizes proprietary synthetic libraries for rapid VHH (single-domain antibody) discovery, allowing for the customization of sensors to specific targets. The company combines microfluidics, machine learning, and advanced optics to translate biological signals into actionable data, providing alternatives to traditional, sporadic laboratory sampling methods.

QBI serves clients across the life sciences, pharmaceutical, water treatment, and environmental monitoring sectors by providing tools for process control, real-time quality assurance, and early warning systems. Their technology has been validated through numerous R&D projects supported by federal agencies including the NIH, DOE, DARPA, IARPA, USDA, EPA, and NOAA. By deploying these robust, field-deployable platforms, QBI helps partners reduce labor, automate complex monitoring workflows, and improve decision-making in both industrial and environmental settings. The company frequently collaborates with academic and commercial partners to demonstrate the utility and field robustness of its sensing technologies.

Halo home
Partner smarter. Move faster.
Get new partnering requests
delivered to your inbox.